Generic Mycapssa Availability
Last updated on Jan 8, 2025.
Mycapssa is a brand name of octreotide, approved by the FDA in the following formulation(s):
MYCAPSSA (octreotide acetate - capsule, delayed release;oral)
-
Manufacturer: CHIESI
Approval date: June 26, 2020
Strength(s): EQ 20MG BASE [RLD]
Has a generic version of Mycapssa been approved?
No. There is currently no therapeutically equivalent version of Mycapssa available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Mycapssa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Method of treating diseases
Patent 10,238,709
Issued: March 26, 2019
Inventor(s): Mamluk Roni & Teichman Sam L.
Assignee(s): Chiasma, Inc.Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
Patent expiration dates:
- February 3, 2036✓
- February 3, 2036
-
Method of treating diseases
Patent 10,695,397
Issued: June 30, 2020
Inventor(s): Mamluk Roni & Teichman Sam L.
Assignee(s): Chiasma, Inc.Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
Patent expiration dates:
- February 3, 2036✓
- February 3, 2036
-
Method of treating diseases
Patent 11,052,126
Issued: July 6, 2021
Inventor(s): Mamluk Roni & Teichman Sam L.
Assignee(s): Chiasma, Inc.Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
Patent expiration dates:
- February 3, 2036✓
- February 3, 2036
-
Oral octreotide therapy and contraceptive methods
Patent 11,141,457
Issued: October 12, 2021
Inventor(s): Haviv Asi & Stevens Ruth Engle & Dawkins Jennings Ray
Assignee(s): AMRYT ENDO, INC.This invention relates to methods of administering oral octreotide therapy to a female subject relating to avoidance of combined oral contraceptives or use of a back-up method for contraception.
Patent expiration dates:
- December 28, 2040✓
- December 28, 2040
-
Patent 11,338,011
Patent expiration dates:
- February 3, 2036✓
- February 3, 2036
-
Method of treating diseases
Patent 11,510,963
Issued: November 29, 2022
Inventor(s): Mamluk Roni & Teichman Sam
Assignee(s): Amryt Endo, Inc.Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
Patent expiration dates:
- February 3, 2036✓
- February 3, 2036
-
Patent 11,857,595
Patent expiration dates:
- February 3, 2036✓
- February 3, 2036
-
Patent 11,890,316
Patent expiration dates:
- December 28, 2040✓
- December 28, 2040
-
Patent 11,969,471
Patent expiration dates:
- September 17, 2029✓
- September 17, 2029
-
Patent 11,986,529
Patent expiration dates:
- September 17, 2029✓
- September 17, 2029
-
Pharmaceutical compositions and related methods of delivery
Patent 8,329,198
Issued: December 11, 2012
Inventor(s): Salama Paul & Mamluk Roni & Marom Karen & Weinstein Irina & Tzabari Moshe
Assignee(s): Chiasma Inc.The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.
Patent expiration dates:
- September 17, 2029✓
- September 17, 2029
-
Pharmaceutical compositions and related methods of delivery
Patent 8,535,695
Issued: September 17, 2013
Inventor(s): Salama Paul & Mamluk Roni & Marom Karen & Weinstein Irina & Tzabari Moshe
Assignee(s): Chiasma Inc.The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.
Patent expiration dates:
- September 17, 2029✓
- September 17, 2029
-
Pharmaceutical compositions and related methods of delivery
Patent 9,265,812
Issued: February 23, 2016
Inventor(s): Mamluk Roni & Tzabari Moshe & Marom Karen & Salama Paul & Weinstein IrinaThe pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.
Patent expiration dates:
- September 17, 2029✓
- September 17, 2029
-
Pharmaceutical compositions and related methods of delivery
Patent 9,566,246
Issued: February 14, 2017
Inventor(s): Mamluk Roni & Tzabari Moshe & Marom Karen & Salama Paul & Weinstein Irina
Assignee(s): CHIASMA INC.The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.
Patent expiration dates:
- September 17, 2029✓
- September 17, 2029
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- June 26, 2027 - LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHO HAVE RESPONDED TO AND TOLERATED TREATMENT WITH OCTREOTIDE OR LANREOTIDE
More about Mycapssa (octreotide)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: somatostatin and somatostatin analogs
- Breastfeeding
- En español
Patient resources
Other brands
Sandostatin, Sandostatin LAR Depot, Bynfezia Pen
Professional resources
Other brands
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.